Canadian application, no grantCanada
Triazole derivatives and pharmaceutical compositions comprising them
CA 2420727 A1 · Owner: Sanofi-Synthelabo · Inventors: Frehel, Daniel; Varkonyine Schlovicsko, Erika; Heja, Gergely
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, solvates hydrates and polymorphs. These , compounds are powerful and selective CCK1 receptor agonists.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledOctober 25, 2001
GrantedNo grant recorded
Term endedOctober 25, 2021
Patent numberCA 2420727 A1
Classification (IPC)C07D403/12 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.